Nodal status-its impact on prognosis in advanced ovarian cancer

Journal of Cancer Research and Clinical Oncology

Volumn 138, Issue 2, 2012, Pages 261-267

  Bachmann, C ^a   Bachmann, S ^a   Fehm, T ^a   Staebler, A ^b   Becker, S ^a   Rothmund, R ^a   Gardanis, C ^a   Grischke, E M ^a   Wallwiener, D ^a   Solomayer, E F ^c  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c SAARLAND UNIVERSITY   (Germany)

Author keywords

Advanced ovarian cancer; Lymphadenectomy; Node status; Prognosis; Residual tumor

Indexed keywords

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER GRADING; CANCER INVASION; CANCER LOCALIZATION; CANCER PROGNOSIS; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HUMAN; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MAJOR CLINICAL STUDY; MINIMAL RESIDUAL DISEASE; OUTCOME ASSESSMENT; OVARY CANCER; OVERALL SURVIVAL; PATIENT ASSESSMENT; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPH NODE EXCISION; LYMPH NODES; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM STAGING; NEOPLASM, RESIDUAL; OVARIAN NEOPLASMS; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 84856895688     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-011-1094-x     Document Type: Article

References (26)

1. Abe A, Furumoto H, Irahara M, Ino H, Kamada M, Naka O, Sasaki M, Kagawa T, Okitsu O, Kushiki N (2010) The impact of systematic para-aortic and pelvic lymphadenectomy on survival in patients with optimally debulked ovarian cancer. J Obstet Gynaecol Res 36 (5): 1023-1030
2. Aletti GD, Dowdy S et al (2006) Role of lymphadenectomy in the management of grossly apparent advanced stage epithelial ovarian cancer. Am J Obstet Gynecol 195 (6): 1862-1868 (Pubitemid 44792638)
3. Balbi G, Manganaro MA, Monteverde A, Landino I, Franzese C, Gioia F (2009) Ovarian cancer: lymphnode metastases. Eur J Gynaecol Oncol 30 (3): 289-291
4. Bristow RE, Tomacruz RS et al (2002) Survival eVect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 20 (5): 1248-1259 (Pubitemid 34177431)
5. Carnino F, Fuda G et al (1997) SigniWcance of lymph node sampling in epithelial carcinoma of the ovary. Gynecol Oncol 65 (3): 467-472 (Pubitemid 27255990)
6. Chan JK, Urban R et al (2007) The potential therapeutic role of lymph node resection in epithelial ovarian cancer: a study of 13918 patients. Br J Cancer 96 (12): 1817-1822 (Pubitemid 46912018)
7. Crawford SC, Vasey PA et al (2005) Does aggressive surgery only beneWt patients with less advanced ovarian cancer? Results from an international comparison within the SCOTROC-1 trial. J Clin Oncol 23 (34): 8802-8811 (Pubitemid 46211526)
8. di Re F, Baiocchi G, Fontanelli R, Grosso G, Cobellis L, Raspagliesi F, di Re E (1996) Systematic pelvic and paraaortic lymphadenectomy for advanced ovarian cancer: prognostic signiWcance of node metastases. Gynecol Oncol 62 (3): 5-360
9. Du Bois A et al (2009) Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials. Cancer 15: 1234-1244
10. Eisenkop SM, Friedman RL et al (1998) Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study. Gynecol Oncol 69 (2): 103-108 (Pubitemid 28246994)
11. Harter P, Bois A et al (2006) Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial. Ann Surg Oncol 13 (12): 1702-1710 (Pubitemid 44951480)
12. Harter P, Gnauert K et al (2007) Pattern and clinical predictors of lymph node metastases in epithelial ovarian cancer. Int J Gynecol Cancer 17: 1238-1244 (Pubitemid 350077354)
13. Harter P, Hahmann M, Lueck HJ, Poelcher M, Wimberger P, Ortmann O, Canzler U, Richter B, Wagner U, Hasenburg A, Burges A, Loibl S, Meier W, Huober J, Fink D, Schroeder W, Muenstedt K, Schmalfeldt B, Emons G, du Bois A (2009) Surgery for recurrent ovarian cancer: role of peritoneal carcinomatosis: exploratory analysis of the DESKTOP I trial about risk factors, surgical implications, and prognostic value of peritoneal carcinomatosis. Ann Surg Oncol 16: 1324-1330
14. Hoskins WJ, McGuir WP et al (1994) The eVect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am J Obstet Gynecol 70 (4): 974-979
15. Kaku T, Ogawa S et al (2003) Histological classiWcation of ovarian cancer. Med Electron Microsc 36 (1): 9-17
16. Kim HS et al (2010) Systematic lymphadenectomy for survival in epithelial ovarian cancer. Int J Gynecol Cancer 20 (4): 520-528
17. Mayr D, Diebold J (2000) Grading of ovarian carcinomas. Int J Gynecol Pathol 19 (4): 348-353
18. Onda T, Yoshikawa H et al (1998) Patients with ovarian carcinoma upstaged to stage III after systematic lymphadenctomy have similar survival to stage I/II patients and superior survival to other stage III patients. Cancer 83 (8): 1555-1560 (Pubitemid 28465473)
19. Panici PB, Maggioni A et al (2005) Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: a randomized clinical trial. J Natl Cancer Inst 97 (8): 560-566 (Pubitemid 40723783)
20. Runnebaum IB, Stickeler E (2001) Epidemiological and molecular aspects of ovarian cancer risk. J Cancer Res Clin Oncol 127 (2): 73-79
21. Saygili (2002) The eVect of ascites, mass volume, and peritoneal carcinomatosis on serum CA125 levels in patients with ovarian carcinoma. Int J Gynecol Cancer 12 (5): 438-442
22. Scarabelli C, Gallo A et al (1997) Systematic pelvic and para-aortic lymphadenectomy in advanced ovarian cancer patients with no residual intraperitoneal disease. Int J Gynecol Cancer 7 (1): 18-26 (Pubitemid 27010013)
23. Stickeler E, Klar M, Watermann D, Geibel A, Földi M, Hasenburg A, Gitsch G (2009) Pegylated liposomal doxorubicin and trastuzumab as 1st and 2nd line therapy in her2/neu positive metastatic breast cancer: a multicenter phase II trial. Breast Cancer Res Treat 17: 591-598
24. Takeshima N et al (2005) Lymph node metastasis in ovarian cancer: diVerence between serous and non-serous primary tumors. Gynecol Oncol 99 (2): 427-431 (Pubitemid 41502856)
25. Whittemore AS (1994) Characteristics relating to ovarian cancer risk: implications for prevention and detection. Gynecol Oncol 55 (3 Pt 2): S15-S19
26. Wimberger P, Lehmann N, Kimmig R, Burges A, Meier W, Du Bois A, Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (2007) Prognostic factors for complete debulking in advanced ovarian cancer, its impact on survival. An exploratory analysis of a prospectively randomized phase III study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR). Gynecol Oncol 106 (1): 69-74 (Pubitemid 46898573)